FDA par­tial­ly halts Nurix Ther­a­peu­tics’ can­cer tri­al as it im­proves man­u­fac­tur­ing process

The FDA is paus­ing pa­tient en­roll­ment and screen­ing for Nurix Ther­a­peu­tics’ Phase I clin­i­cal tri­al for a po­ten­tial drug to treat B-cell ma­lig­nan­cies in can­cer pa­tients.

The agency is halt­ing the tri­al af­ter Nurix told the FDA it is im­prov­ing the man­u­fac­tur­ing process of the po­ten­tial drug, known as NX-2127, which is a de­grad­er of BTK and IMiD neo­sub­strates.

Nurix is in com­mu­ni­ca­tion with the FDA to “in­tro­duce the im­proved NX-2127 man­u­fac­tur­ing process and drug prod­uct in­to our clin­i­cal de­vel­op­ment plan,” CEO Arthur Sands said in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.